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Objectives: Rapid and accurate sexually transmitted infection diagnosis can reduce onward transmission
and improve treatment efﬁcacy. We evaluated the accuracy of a 15-minute run-time recombinase po-
lymerase ampliﬁcationebased prototype point-of-care test (TwistDx) for Chlamydia trachomatis (CT) and
Neisseria gonorrhoeae (NG).
Methods: Prospective, multicentre study of symptomatic and asymptomatic patients attending three
English sexual health clinics. Research samples provided were additional self-collected vulvovaginal
swab (SCVS) (female participants) and ﬁrst-catch urine (FCU) aliquot (female and male participants).
Samples were processed blind to the comparator (routine clinic CT/NG nucleic acid ampliﬁcation test
(NAAT)) results. Discrepancies were resolved using Cepheid CT/NG GeneXpert.
Results: Both recombinase polymerase ampliﬁcation and routine clinic NAAT results were available for
392 male and 395 female participants. CT positivity was 8.9% (35/392) (male FCU), 7.3% (29/395) (female
FCU) and 7.1% (28/395) (SCVS). Corresponding NG positivity was 3.1% (12/392), 0.8% (3/395) and 0.8% (3/
395). Speciﬁcity and positive predictive values were 100% for all sample types and both organisms,
except male CT FCU (99.7% speciﬁcity (95% conﬁdence interval (CI) 98.4e100.0; 356/357), 97.1% positive
predictive value (95% CI 84.7e99.9; 33/34)). For CT, sensitivity was 94.3% for FCU and SCVS. CT
sensitivity for female FCU was higher (100%; 95% CI, 88.1e100; 29/29) than for SCVS (96.4%; 95% CI, 81.7
e99.9; 27/28). NG sensitivity and negative predictive values were 100% in FCU (male and female).
Conclusions: This prototype test has excellent performance characteristics, comparable to currently used
NAATs, and fulﬁls several World Health Organization ASSURED criteria. Its rapidity without loss of
performance suggests that once further developed and commercialized, this test could positively affect
clinical practice and public health. E.M. Harding-Esch, Clin Microbiol Infect 2018;▪:1
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Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are
major contributors to the burden of sexually transmitted infections
(STIs) in England and elsewhere [1,2]. They are frequentlyof Clinical Microbiology and Infectious Diseases. This is an open access article under
curacy of a prototype rapid chlamydia and gonorrhoea recombinase
cal evaluation, Clinical Microbiology and Infection (2018), https://
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agnosed, and if untreated they can lead to serious complications [4,5].
Currently, it can take up to 2 weeks to obtain CT and NG results
and treatment after STI testing in sexual health clinics (SHCs) in the
UK [6], but delays may be considerably longer in other settings [7].
During this period, sexual risk taking may continue, including
acquisition of new partners [8]. Rapid and accurate CT/NG point-of-
care tests (POCTs), enabling diagnosis and treatment of infected
patients within the same clinical visit [9] (a ‘test and treat’ strategy),
could potentially reduce rates of inappropriate presumptive treat-
ment, shorten time to treatment, decrease rates of untreated CTand
NG for patients lost to follow-up, limit onward transmission and
reduce rates of sequelae [10e12].
British Association for Sexual Health and HIV guidelines state
that CT and NG detection must use nucleic acid ampliﬁcation tests
(NAATs) (and/or culture for NG) [5,13]. A number of rapid and
point-of-care NAAT-based tests for CT and NG are being or have
recently been developed [14]. Newer NAAT technologies that use
isothermal ampliﬁcation, avoiding the need for thermal cycling,
have the potential to enable fast turnaround times from sample to
result. TwistDx (Cambridge, UK) have developed an isothermal
recombinase polymerase ampliﬁcation (RPA) method, which can
detect CT/NG infection (single NG target) in approximately 15 mi-
nutes, requires no thermal cycling, can be battery powered and has
a reaction temperature of 37C. The RPA CT/NG assay is run on an
Alere i instrument (Alere, Waltham, MA, USA). The TwistDx RPA CT/
NG assay is therefore an excellent candidate for development as a
true molecular CT/NG POCT, allowing for test and treat pathways in
SHCs, community and resource-poor settings [15].
We aimed to assess the diagnostic accuracy of the prototype
TwistDx RPA assay for genital CT and NG detection on prospectively
collected clinical samples from men and women in English SHCs.
Methods
Ethical approval was granted by the London Bridge Research
Ethics Committee (13/LO/0691). This report was written following
Standards for Reporting Diagnostic Accuracy guidelines
(Supplementary Table S1) [16].
Sample size and recruitment
This prospective multicentre diagnostic accuracy evaluationwas
powered to obtain a minimum of 50 CT and 20 NG positive and 200
negative, samples for both male and female participants. Assuming
92% sensitivity and 99% speciﬁcity of the RPA CT/NG assay
compared to standard NAATs, the 95% conﬁdence intervals (CIs)
obtained would be 81.2 to 96.8 and 96.4 to 99.9, respectively.
Assuming a CT prevalence of 8.3% (based on Genito-Urinary
Medicine Clinical Activity Data set (GUMCAD) [17] from the South
London SHC), 600 individuals would lead to the requisite number of
CT-positive and -negative samples. With a lower expected NG
prevalence of 3%, 800 participants were needed. In order to allow
subgroup analysis by gender, we planned to recruit 400 men and
400 women.
Study sites and participant selection
Three SHCs located in South London, Yorkshire and on the south
coast of England participated. Eligible patients were recruited
during routine consultations by clinic staff using the following
eligibility criteria: age 16 years; attending the SHC; had not
passed urine in the previous 2 hours; provided written informed
consent for the collection of research samples; provided all sample
types (men: ﬁrst-catch urine (FCU) and meatal swabs before andPlease cite this article in press as: Harding-Esch EM, et al., Diagnostic ac
polymerase ampliﬁcation assay: a multicentre cross-sectional preclini
doi.org/10.1016/j.cmi.2018.06.003after micturition; women: FCU and self-collected vulvovaginal
swabs (SCVS)). Participant demographic and clinical data were
collected on case report forms.
Sample collection and processing
All samples for this evaluation were self-taken by participants
after collection of routine clinical samples. A minimum volume of
20mL FCUwas collected frommale subjects; an aliquot of 2 to 3mL
was taken for routine clinical testing, and the remainder was
immediately stored at 2 to 8C until shipment (twice weekly) on
wet ice to TwistDx for RPA CT/NG testing. In addition, male par-
ticipants were asked to self-collect two external penile meatal
swabs, one before urination and the second after urination.
Womenprovided two SCVS, the ﬁrst for the clinic's routine CT/NG
NAAT, followed by an FCU specimen. FCU from female participants
was processed as per FCU from male participants, except that no al-
iquots for routine CT/NG NAAT testing were taken. Research SCVS
samples were eluted in clinic within 10 minutes of collection. Swabs
were immersed and swirled in 1 mL lysis buffer for 5 seconds, left to
stand in the lysis buffer for 90 seconds and then disposed of.
Neutralization buffer (2 mL) was added to the lysis buffer and the
tube inverted ten times. Tubeswere storedat20C (or lower) before
shipment (twiceweekly) ondry ice toTwistDx for RPACT/NG testing.
Sample testing and resolution of discrepant results
Routine clinical NAAT testing was performed locally on male
FCU and female SCVS samples, as per clinic standard practice (BD
Viper CT/NG assay (Becton Dickinson, Oxford, UK) at the South
London clinic; GenProbe Aptima CT/NG test (Hologic Gen-Probe,
Marlborough, MA, USA) at the other clinics).
Research sample processing and testing were in accordance
with TwistDx protocols, developed through internal optimization
(unpublished data). The RPA CT/NG assay was performed on
research samples (FCU for men, FCU and SCVS for women) by staff
at TwistDx, who were unaware of the routine clinic NAAT and case
report form results. FCU samples were processed through a size-
exclusion chromatography device (Zeta Sep FPLC Desalting Col-
umns; Generon, Slough, UK) for the purposes of desalting the
sample before testing on the Alere i instrument.
The comparator test for male FCU samples was the routine clinic
NAAT performed on male FCU; that for female SCVS and FCU was
the routine clinic NAAT on female SCVS samples. Data were sent to
the Applied Diagnostic Research & Evaluation Unit (ADREU), St
George's University of London, where the routine clinic NAAT and
RPA CT/NG assay results were compared for each participant and
sample type. We deﬁned the reference standard [16] as the routine
clinic NAAT result when in agreement with the RPA CT/NG assay
and no further testing was performed. Otherwise, all sample elu-
ates from patients where a discrepant result had been found were
tested at the TwistDx facility using the CT/NG GeneXpert as per
manufacturer's instructions, with the sample type (FCU or swab)
and initial CT or NG results masked. In these cases, the reference
standard was deﬁned as the resolved result when two out of three
of the test results were in agreement.
Data and statistical analysis
Data were entered into a database by ADREU. Participants for
whom either the RPA CT/NG or routine clinic NAAT results were
missing and/or who did not provide both sample types (swab and
FCU) in the case of women, as per eligibility criteria, were excluded
from analyses. Calculation of RPA CT/NG assay diagnostic accuracy
measures (sensitivity, speciﬁcity, positive predictive value (PPV)curacy of a prototype rapid chlamydia and gonorrhoea recombinase
cal evaluation, Clinical Microbiology and Infection (2018), https://
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CIs was carried against the reference standard. Comparison of
performance by subgroup (symptomatic vs. asymptomatic; female
FCU vs. SCVS) was performed by the Pearson chi-square statistic. All
analyses were conducted by Stata 12.0 software (StataCorp, College
Station, TX, USA).
Results
Overview of participants
Recruitment took place May to September 2014. A total of 414
men and 442 women provided written informed consent (Figs. 1
and 2). Both RPA CT/NG assay and routine clinic NAAT results
were available for FCU for 392 (94.7%) of 414 men. A total of 395
(89.7%) of 442 women had both FCU and SCVS results available for
all tests performed (RPA CT/NG for FCU and SCVS; routine clinic
NAAT for SCVS). Participant characteristics are summarized in
Table 1. Study CT positivity was 35 (8.9%) of 392 for male FCU, 29
(7.3%) of 395 for female FCU and 28 (7.1%) of 395 for SCVS. Corre-
sponding NG positivities were 12 (3.1%) of 382, three (0.8%) of 395
and three (0.8%) of 395 (Table 2).
CT/NG RPA assay diagnostic accuracy
Table 2 summarizes the RPA CT/NG assay diagnostic accuracy
estimates (Supplementary Table S2). In three (0.8%) of 392 FCU
samples, RPA CT/NG results disagreed with routine clinic NAAT
results for CT only (there were no NG discrepant results)
(Supplementary Table S3A). After discrepant testing, zero of three
RPA CT/NG results agreed with the resolved result. Subsequently, in
men, all diagnostic accuracy measures were 100% for NG (12/12;
95% CI, 73.5e100 for sensitivity and PPV; 380/380; 95% CI,
99.0e100 for speciﬁcity and NPV). For CT, speciﬁcity and NPV were
99.4% (356/357; 95% CI, 98.4e100 and 356/358; 95% CI,
98.0e99.9, respectively), PPV was 97.1% (33/34; 95% CI, 84.7e99.9)
and sensitivity was 94.3% (33/35; 95% CI, 80.8e99.3) (Table 2).Fig. 1. Patient and sample ﬂo
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the RPA CT/NG assay (Table 2). For CT, six (0.76%) of 790 (three FCU,
three SCVS) results disagreed with the routine clinic NAAT SCVS
result (Supplementary Table S3B). After discrepant testing, the RPA
CT/NG assay agreed with the resolved result for all three FCU
discrepant results and two of three SCVS discrepant results. For NG,
seven (0.89%) of 790 (three FCU, four SCVS) RPA CT/NG results
disagreed with the routine clinic NAAT SCVS result (Supplementary
Table S3B). Of these, all three FCU and three of four SCVS discrepant
results agreed with the resolved result. Thus, in women, all mea-
sures of diagnostic accuracy were 100% for FCU for both CT and NG.
For CT and NG in SCVS, speciﬁcity and PPV were 100%, NPV was
99.7% (367/368; 95% CI, 98.5e100) and sensitivity was 96.4% (27/
28; 95% CI, 81.7e100) for CT and 66.7% (2/3; 95% CI, 9.0e100) for NG
(Table 2). No female subject had a discrepant result for both CT and
NG.
When performance was analysed by participant-reported
symptomatic status, there was no evidence of a signiﬁcant differ-
ence between symptomatic and asymptomatic patients (p > 0.05).
All point estimates were 100% for asymptomatic participants
(Table 2). Among symptomatic participants (Table 2), the RPA CT/
NG assay's sensitivity was lower: 15 (93.8%) of 16 (95% CI,
69.8e99.8) for male CT FCU and 13 (92.9%) of 14 (95% CI, 66.1e99.8)
for female CT SCVS, but speciﬁcity and NPV remained high. In
addition, all diagnostic accuracy measures for NG detection in both
male and female FCU and female CT FCU detection were 100%,
regardless of symptomatic status (Supplementary Table S2).
Discussion
In this diagnostic accuracy evaluation of a prototype ultrarapid
isothermal RPA assay for detection of CT and NG, performance
(sensitivity, speciﬁcity, PPV and NPV) against the reference stan-
dard for CT was >94% for all sample types evaluated (male FCU;
female FCU and SCVS). Performance for NG was 100% except for
SCVS sensitivity and NPV; it was however not possible to assess NG
sensitivity and PPV in women conﬁdently because of the loww for male participants.
curacy of a prototype rapid chlamydia and gonorrhoea recombinase
cal evaluation, Clinical Microbiology and Infection (2018), https://
Fig. 2. Patient and sample ﬂow for female participants.
Table 1
Participant characteristics
Characteristic Male participants Female participants
Total Positive for CT Positive for NG Total Positive for CT Positive for NG
Age
16e19 years 15 (3.8) 1 (6.7) 0 40 (10.1) 5 (12.5) 0
20e24 years 126 (32.1) 22 (17.5) 6 (4.8) 157 (39.7) 18 (11.5) 0
25e34 years 148 (37.8) 11 (7.4) 2 (1.4) 140 (35.4) 4 (2.9) 1 (0.7)
35e44 years 64 (16.3) 0 3 (4.7) 41 (10.4) 1 (2.4) 1 (2.4)
45e64 years 37 (9.4) 1 (2.7) 1 (2.7) 16 (4.1) 0 0
65þ years 2 (0.5) 0 0 1 (0.3) 0 0
Clinic
1 127 (32.4) 13 (10.2) 7 (5.5) 157 (39.7) 8 (5.1) 2 (1.3)
2 186 (47.4) 18 (9.7) 4 (2.2) 161 (40.8) 16 (9.9) 1 (0.6)
3 79 (20.2) 4 (5.1) 1 (1.3) 77 (19.5) 4 (5.2) 0
Contact
No 340 (87.4) 18 (5.3) 10 (2.9) 363 (92.8) 16 (4.4) 2 (0.6)
CT only 33 (8.5) 14 (42.4) 2 (6.1) 22 (5.6) 11 (50.0) 0
NG only 7 (1.8) 2 (28.6) 0 1 (0.3) 0 1 (100)
Both CT and NG 9 (2.3) 1 (11.1) 0 5 (1.3) 0 0
Received CT/NG active medication since test/6 weeks before test
No 375 (95.7) 34 (9.1) 11 (2.9) 367 (92.9) 27 (7.4) 3 (0.8)
Yes 17 (4.3) 1 (5.9) 1 (5.9) 28 (7.1) 1 (3.6) 0
Symptomatic
No 249 (63.7) 18 (7.2) 2 (0.8) 208 (52.8) 14 (6.7) 1 (0.5)
Yes 142 (36.3) 16 (11.3) 10 (7.0) 186 (47.2) 14 (7.5) 2 (1.1)
Currently menstruating
No 368 (93.4) 28 (7.6) 3 (0.8)
Yes 26 (6.6) 0 0
Data are presented as n (%). CT and NG positivity was deﬁned as reference standard (positive by at least two of three tests: clinic NAAT, RPA CT/NG assay, Cepheid GeneXpert).
Male participants were considered symptomatic if they reported one or more of: discharge (clear or cloudy liquid from penis); irritation at top of penis; itching; needing to
pass urine more often than usual; pain/burning when urinating. Female participants were considered symptomatic if they reported one or more: itching; discharge (clear or
cloudy liquid from vagina); pain/burning when urinating; needing to pass urine more frequently; pain during sex; bleeding after sex; bleeding in between periods; pelvic
abdominal pain.
CT, Chlamydia trachomatis; NAAT, nucleic acid ampliﬁcation test; NG, Neisseria gonorrhoeae; RPA, recombinase polymerase ampliﬁcation.
E.M. Harding-Esch et al. / Clinical Microbiology and Infection xxx (2018) 1e74numbers of positive results. The RPA CT/NG also demonstrated
excellent technical performance, as no inhibitory results and very
few RPA CT/NG assay device errors were observed.
With respect to rapidity, the RPA CT/NG assay's sample prepa-
ration, ampliﬁcation and detection take place in less than 20 mi-
nutes, including sample preparation and RPA CT/NG assay run time.
A simple-to-use desalting device has been included in newerPlease cite this article in press as: Harding-Esch EM, et al., Diagnostic ac
polymerase ampliﬁcation assay: a multicentre cross-sectional preclini
doi.org/10.1016/j.cmi.2018.06.003iterations of the assay, allowing immediate (in seconds) processing
of FCU samples before running the assay, although currently it is
only appropriate for research laboratory use. The test's rapidity
enhances the possibility of implementation as a POCT, enabling test
and treat strategies with patients diagnosed and treated in the
same clinical visit, and is potentially rapid enough to be incorpo-
rated into clinical practice with minimal change to clinicalcuracy of a prototype rapid chlamydia and gonorrhoea recombinase
cal evaluation, Clinical Microbiology and Infection (2018), https://
Table 2
RPA CT/NG assay performance
Characteristic Male participants Female participants
FCU FCU SCVS
CT NG CT NG CT NG
All participants
No. positive/total 35/392 12/392 29/395 3/395 28/395 3/395
Positive 8.9% 3.1% 7.3% 0.8% 7.1% 0.8%
Sensitivity (%, 95% CI), n/N 94.3 (80.8e99.3),
33/35
100 (73.5e100),
12/12
100 (88.1e100),
29/29
100 (29.2e100),
3/3
96.4 (81.7e99.9),
27/28
66.7 (9.0e100),
2/3
Speciﬁcity (%, 95% CI), n/N 99.7 (98.4e100),
356/357
100 (99.0e100),
380/380
100 (99.0e100),
366/366
100 (99.1e100),
392/392
100 (99.0e100),
367/367
100 (99.1e100),
392/392
PPV (%, 95% CI), n/N 97.1 (84.7e99.9),
33/34
100 (73.5e100),
12/12
100 (88.1e100),
29/29
100 (29.2e100),
3/3
100 (87.2e100),
27/27
100 (15.8e100),
2/2
NPV (%, 95% CI), n/N 99.4 (98.0e99.9),
356/358
100 (99.0e100),
380/380
100 (99.0e100),
366/366
100 (99.1e100),
392/392
99.7 (98.5e100),
367/368
99.7 (98.6e100),
392/393
Symptomatic participants
No. positive/total 16/142 10/142 14/186 2/186 14/186 2/186
Positive 11.3% 7.0% 7.5% 1.1% 7.5% 1.1%
Sensitivity (%, 95% CI), n/N 93.8 (69.8e99.8),
15/16
100 (69.2e100),
10/10
100 (76.8e100),
14/14
100 (15.8e100),
2/2
92.9 (66.1e99.8),
13/14
50 (1.3e98.7),
1/2
Speciﬁcity (%, 95% CI), n/N 99.2 (95.7e100),
125/126
100 (97.2e100),
132/132
100 (97.9e100),
172/172
100 (98.0e100),
184/184
100 (97.9e100),
172/172
100 (98.0e100),
184/184
PPV (%, 95% CI), n/N 93.8 (69.8e99.8),
15/16
100 (69.2e100),
10/10
100 (76.8e100),
14/14
100 (15.8e100),
2/2
100 (75.3e100),
13/13
100 (2.5e100),
1/1
NPV (%, 95% CI), n/N 99.2 (95.7e100),
125/126
100 (97.2e100),
132/132
100 (97.9e100),
172/172
100 (98.0e100),
184/184
99.4 (96.8e100),
172/173
99.5 (97.0e100),
184/185
Asymptomatic participants
No. positive/total 18/249 2/249 15/208 1/208 14/208 1/208
Positive 7.2% 0.8% 7.2% 0.48% 6.7% 0.48%
Sensitivity (%, 95% CI), n/N 100 (81.5e100),
18/18
100 (15.8e100),
2/2
100 (78.2e100),
15/15
100 (2.5e100),
1/1
100 (76.8e100),
14/14
100 (2.5e100),
1/1
Speciﬁcity (%, 95% CI), n/N 100 (98.4e100),
231/231
100 (98.5e100),
247/247
100 (98.1e100),
193/193
100 (98.2e100),
207/207
100 (98.1e100),
194/194
100 (98.2e100),
207/207
PPV (%, 95% CI), n/N 100 (81.5e100),
18/18
100 (15.8e100),
2/2
100 (78.2e100),
15/15
100 (2.5e100),
1/1
100 (76.8e100),
14/14
100 (2.5e100),
1/1
NPV (%, 95% CI), n/N 100 (98.4e100),
231/231
100 (98.5e100),
247/247
100 (98.1e100),
193/193
100 (98.2e100),
207/207
100 (98.1e100),
194/194
100 (98.2e100),
207/207
CT and NG positivity was deﬁned as reference standard (positive by at least two of three tests: clinic NAAT, RPA CT/NG assay, Cepheid GeneXpert). Male participants were
considered symptomatic if they reported one or more of: discharge (clear or cloudy liquid from penis); irritation at top of penis; itching; needing to pass urine more often than
usual; pain/burning when urinating. Female participants were considered symptomatic if they reported one or more: itching; discharge (clear or cloudy liquid from vagina);
pain/burning when urinating; needing to pass urine more frequently; pain during sex; bleeding after sex; bleeding in between periods; pelvic abdominal pain.
CI, conﬁdence interval; CT, Chlamydia trachomatis; FCU, ﬁrst-catch urine; NAAT, nucleic acid ampliﬁcation test; NG, Neisseria gonorrhoeae; NPV, negative predictive value; PPV,
positive predictive value; RPA, recombinase polymerase ampliﬁcation; SCVS, self-collected vulvovaginal swab.
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mentation has been patient willingness to wait, even for a 90-
minute rapid test [11,18], and the major changes to clinic care
pathways necessary to incorporate rapid tests as POCTs as part of
SHC consultations [11,12]. Consequently, CT/NG GeneXpert imple-
mentation has enabled a same-day or next-day results service,
rather than a POCT test and treat strategy [19e21]. The RPA CT/NG
assay's rapidity, combined with its high performance, therefore has
the potential to revolutionize STI diagnosis and management.
Furthermore, the RPA CT/NG assay would be well suited for use
in nonlaboratory conditions, both in low- and high-income coun-
tries, because of its limited operational requirements. In resource-
limited settings, laboratory services for STIs are either not avail-
able or are difﬁcult to access (physically and/or ﬁnancially) and the
development and introduction of affordable STI POCTs are part of
the strategic direction of the World Health Organization (WHO)
[22]. The RPA CT/NG assay fulﬁls many of the ASSURED criteria,
developed by WHO as a benchmark to decide if tests address dis-
ease control needs in developing countries [23], and could there-
fore be an excellent candidate for a true CT/NG POCT in multiple
settings.
British Association for Sexual Health and HIV guidelines for NG
testing indicate a minimum PPV of 90%; below this, positive results
should be conﬁrmed with supplementary testing using a different
nucleic acid target from the original test [5]. Although our NG PPVPlease cite this article in press as: Harding-Esch EM, et al., Diagnostic ac
polymerase ampliﬁcation assay: a multicentre cross-sectional preclini
doi.org/10.1016/j.cmi.2018.06.003point estimates were all 100%, the lower 95% CI were all <90%. As
the RPA CT/NG assay has only a single NG molecular target, it may
ultimately have lower speciﬁcity and PPV compared to two-target
assays, especially if applied to lower prevalence settings. That
said, a diagnostic evaluation with large sample size of the two-
target GeneXpert by Gaydos et al. [24] also resulted in NG PPVs
with lower 95% CIs <90% in all sample types despite the point es-
timate being >90%, indicating that supplementary testing may be
required for both assay types in low prevalence settings.
The RPA CT/NG assay shows promise for both screening of
asymptomatics and diagnosis of symptomatics, as we found no
signiﬁcant difference in point estimates by symptomatic status, in
accordance with previously reported ﬁndings [24]. Furthermore,
both SCVS and FCU are possible sample types for women. This is
interesting because it has previously been reported that urine is
less sensitive than swabs, probably because of lower bacteria load
[25]; we did not have data on organism load to explore this ﬁnding
further. It is also possible that different sample storage (extracted
SCVS eluate frozen vs. FCU refrigerated before testing) could have
contributed to this ﬁnding. Freezeethaw is unlikely to have
impacted on results (one freezeethaw cycle for FCU before
discrepant testing; and a maximum of two freezeethaw cycles for
SCVS, the ﬁrst for initial testing and the second for discrepant
testing), particularly because CT DNA detection by PCR is unaffected
by extended (2 years) storage [26]. Our results must however becuracy of a prototype rapid chlamydia and gonorrhoea recombinase
cal evaluation, Clinical Microbiology and Infection (2018), https://
E.M. Harding-Esch et al. / Clinical Microbiology and Infection xxx (2018) 1e76interpreted with caution, as it would have been more appropriate
to compare the RPA CT/NG assay FCU results to clinic FCU NAAT
results, had these been available, but female FCU is not routinely
collected in England. Because of the very high performance of the
assay in this evaluation, it is expected that use of the clinic FCU
NAAT as the reference standard would have made little difference.
It is known that the discrepant analysis approach used in this
study can lead to biases, particularly when the assay under evalu-
ation is also part of the algorithm used to deﬁne truly positive and
negative results [27]. However, agreement between the initial clinic
NAAT and RPA CT/NG assay was very high, with few samples
requiring discrepant resolution. Logistical and funding constraints
meant an alternative study design (for example, composite refer-
ence standard or patient infection status as used for US Food and
Drug Administration approval [27]), with a consistent deﬁnition for
all sample types, was not possible.
The results of our evaluation are promising for the further
development of the RPA CT/NG assay, the aims of which should be
to: (a) increase CT sensitivity; (b) ensure the PPV remains >90%; (c)
ensure usability; and (d) perform larger evaluations to achieve
tighter CIs around point estimates, especially for NG. An important
addition to this test's development would be validation of extra-
genital (pharyngeal and rectal) sample types. Extragenital samples
are routinely collected for men who have sex with men, with the
majority of NG infections in men who have sex with men detected
extragenitally [28].
This prototype RPA CT/NG assay had excellent performance
characteristics, comparable to currently used NAATs, and fulﬁls
several WHOASSURED criteria, most notably accuracy, rapidity and
thermostability. Its rapidity without loss of performance suggests
that once further developed and commercialized, this test could
positively affect both clinical practice and public health.
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